Login to Your Account


JUST THE OPENING SALVO?

DUBLIN – Sanofi SA CEO Olivier Brandicourt veered in the direction of hostile territory Thursday by going public with a $9.3 billion all-cash offer for Medivation Inc., following a month of behind-the-scenes overtures that failed to arouse any interest.

more »

Our Habitat for All Things Science
B-cell receptor could be antitumor target

Peptibodies targeting the B-cell receptor might provide a cancer therapy that is personalized to specific tumor cells but can be produced in a relatively automated fashion, making the production of such individualized therapy a realistic possibility.

Preclinical work describing the approach appeared in the April 25, 2016, online issue of the Proceedings of the National Academy of Sciences.

B cells have a truly unique surface protein – their business end, the B-cell receptor or idiotype, which is different on every B cell.

On B cell-derived tumor cells, that READ MORE »

Opinion


Partners in Focus